|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Riaz SP, Lüchtenborg M, Coupland VH,
Spicer J, Peake MD and Møller H: Trends in incidence of small cell
lung cancer and all lung cancer. Lung Cancer. 75:280–284. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Toschi L, Cappuzzo F and Janne PA:
Evolution and future perspectives in the treatment of locally
advanced non-small cell lung cancer. Ann Oncol. 18 Suppl
9:ix150–ix155. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gu L, Deng JZ, Roy S and Hammond PT: A
combination RNAi-chemotherapy layer-by-layer nanoparticle for
systemic targeting of KRAS/P53 with cisplatin to treat non-small
cell lung cancer. Clin Cancer Res. 23:7312–7323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barr MP, Gray SG, Hoffmann AC, Hilger RA,
Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and
O'Byrne KJ: Generation and characterisation of cisplatin-resistant
non-small cell lung cancer cell lines displaying a stem-like
signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pan JY, Sun CC, Bi ZY, Chen ZL, Li SJ, Li
QQ, Wang YX, Bi YY and Li DJ: miR-206/133b Cluster: A Weapon
against lung cancer? Mol Ther Nucleic Acids. 8:442–449. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ni J, Bucci J, Chang L, Malouf D, Graham P
and Li Y: Targeting MicroRNAs in prostate cancer radiotherapy.
Theranostics. 7:3243–3259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ayers D and Vandesompele J: Influence of
microRNAs and long non-coding RNAs in cancer chemoresistance.
Genes. 8(pii): E952017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
|
|
13
|
Yu PN, Yan MD, Lai HC, Huang RL, Chou YC,
Lin WC, Yeh LT and Lin YW: Downregulation of miR-29 contributes to
cisplatin resistance of ovarian cancer cells. Int J Cancer.
134:542–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lawrence CW and Hinkle DC: DNA polymerase
zeta and the control of DNA damage induced mutagenesis in
eukaryotes. Cancer Surv. 28:21–31. 1996.PubMed/NCBI
|
|
15
|
Zhang S, Chen H, Zhao X, Cao J, Tong J, Lu
J, Wu W, Shen H, Wei Q and Lu D: REV3L 3′UTR 460 T>C
polymorphism in microRNA target sites contributes to lung cancer
susceptibility. Oncogene. 32:242–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu F, Lin X, Okuda T and Howell SB: DNA
polymerase zeta regulates cisplatin cytotoxicity, mutagenicity and
the rate of development of cisplatin resistance. Cancer Res.
64:8029–8035. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang L, Shi T, Liu F, Ren C, Wang Z, Li Y,
Tu X, Yang G and Cheng X: REV3L, a promising target in regulating
the chemosensitivity of cervical cancer cells. PLoS One.
10:e01203342015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen
Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes
cisplatin resistance in non-small-cell lung cancer NSCLC.
Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu
LZ and Jiang BH: Downregulation of ATG14 by EGR1-MIR152 sensitizes
ovarian cancer cells to cisplatin-induced apoptosis by inhibiting
cyto-protective autophagy. Autophagy. 11:373–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Wang Y, Song Y, Fu Z and Yu W:
miR-27a regulates cisplatin resistance and metastasis by targeting
RKIP in human lung adenocarcinoma cells. Mol Cancer. 13:1932014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu DW, Wu TC, Wu JY, Cheng YW, Chen YC,
Lee MC, Chen CY and Lee H: Phosphorylation of paxillin confers
cisplatin resistance in non-small cell lung cancer via activating
ERK-mediated Bcl-2 expression. Oncogene. 33:4385–4395. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dehghanzadeh R, Jadidi-Niaragh F, Gharibi
T and Yousefi M: MicroRNA-induced drug resistance in gastric
cancer. Biomed Pharmacother. 74:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou J, Yin F, Wang Q, Zhang W and Li L:
Analysis of microarray-identified genes and microRNAs associated
with drug resistance in ovarian cancer. Int J Clin Exp Pathol.
8:6847–6858. 2015.PubMed/NCBI
|
|
25
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma Y, Li X, Cheng S, Wei W and Li Y:
MicroRNA-106a confers cisplatin resistance in non-small cell lung
cancer A549 cells by targeting adenosine triphosphatase-binding
cassette A1. Mol Med Rep. 11:625–632. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Muniyappa MK, Dowling P, Henry M, Meleady
P, Doolan P, Gammell P, Clynes M and Barron N: MiRNA-29a regulates
the expression of numerous proteins and reduces the invasiveness
and proliferation of human carcinoma cell lines. Eur J Cancer.
45:3104–3118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu Z, Cui Y, Zhou Y, Zhou K, Qiao X, Li C
and Wang S: MicroRNA-29a plays a suppressive role in non-small cell
lung cancer cells via targeting LASP1. Onco Targets Ther.
9:6999–7009. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brondello JM, Pillaire MJ, Rodriguez C,
Gourraud PA, Selves J, Cazaux C and Piette J: Novel evidences for a
tumor suppressor role of Rev3, the catalytic subunit of Pol zeta.
Oncogene. 27:6093–6101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knobel PA, Kotov IN, Felley-Bosco E,
Stahel RA and Marti TM: Inhibition of REV3 expression induces
persistent DNA damage and growth arrest in cancer cells. Neoplasia.
13:961–970. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng
L, Chen D, Zhang Y, Lu Z, Yang J, et al: REV3L confers
chemoresistance to cisplatin in human gliomas: the potential of its
RNAi for synergistic therapy. Neuro Oncol. 11:790–802. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang W, Sheng W, Yu C, Cao J, Zhou J, Wu
J, Zhang H and Zhang S: REV3L modulates cisplatin sensitivity of
non-small cell lung cancer H1299 cells. Oncol Rep. 34:1460–1468.
2015. View Article : Google Scholar : PubMed/NCBI
|
